Trichosporon asahii is a significant yeast-like fungal species found in the environment that can colonize various human organs. It can invade the human body through multiple routes, leading to infections and the development of certain diseases. With the widespread use of immunosuppressants, broad-spectrum antibiotics, and invasive treatments such as tumor radiotherapy, chemotherapy, and organ transplantation, reports of superficial and deep infections caused by
T. asahii have become increasingly common (
1-
3). In vitro drug sensitivity testing and clinical evaluations have demonstrated that this fungus exhibits resistance to most first-line antifungal drugs, except azoles (
4). Treating trichosporosis becomes particularly challenging in cases of disseminated and systemic deep infections (
5), with mortality rates exceeding 77% (
6).
Most studies on
T. asahii have focused on understanding its drug resistance mechanisms and strategies to combat this resistance (
7,
8).
Trichosporon species show low sensitivity to commonly used preventive or empirical antifungal treatments. However, the combination of voriconazole or fluconazole with amphotericin B has demonstrated some therapeutic effectiveness, improving patient outcomes (
9). Given the limited availability of effective antifungal drugs, gaining a better understanding of how
Trichosporon evades the host's antifungal defenses is crucial for improving treatment (
10).
Trichosporon asahii produces several virulence factors, including capsular polysaccharides, biofilms, and extracellular enzyme secretion (
11,
12). Among these, capsular polysaccharides play a pivotal role in the fungus's ability to evade the host's immune system (
13). These polysaccharides reduce the host's immune response, inhibit the antigen-presenting function of monocytes, and act as a protective barrier on the fungal cell wall, preventing effective macrophage phagocytosis and subsequent killing by the immune system (
14). One key capsular polysaccharide, glucuronoxylomannan (GXM), is a high molecular weight antigenic polysaccharide. Studies on
Cryptococcus neoformans have shown that GXM reduces adenosine triphosphate (ATP) production in mouse glial cells, promoting apoptosis (
15).